| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA878: Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 |
|
Medicine details |
|
| Medicine name | nirmatrelvir + ritonavir (Paxlovid®) |
| Formulation | 150 mg +100 mg film-coated tablet |
| Reference number | 5040 |
| Indication | Treatment of COVID 19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID 19 |
| Company | Pfizer Ltd |
| BNF chapter | Infections |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/03/2024 |
| NICE guidance | TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 |